RT Journal Article
SR Electronic
T1 Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.03.20019760
DO 10.1101/2020.02.03.20019760
A1 Mark Jesus M. Magbanua
A1 Lamorna Brown-Swigart
A1 Hsin-Ta Wu
A1 Gillian L. Hirst
A1 Christina Yau
A1 Denise M. Wolf
A1 Antony Tin
A1 Raheleh Salari
A1 Svetlana Shchegrova
A1 Hemant Pawar
A1 Amy L. Delson
A1 Angela DeMichele
A1 Minetta C. Liu
A1 A. Jo Chien
A1 Smita Asare
A1 Cheng-Ho J. Lin
A1 Paul Billings
A1 Alexey Aleshin
A1 Himanshu Sethi
A1 Maggie Louie
A1 Bernhard Zimmermann
A1 Laura J. Esserman
A1 Laura J. van ’t Veer
YR 2020
UL http://medrxiv.org/content/early/2020/02/05/2020.02.03.20019760.abstract
AB Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence in 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2 TRIAL. Cell-free DNA (cfDNA) was isolated from 291 plasma samples collected at pretreatment (T0), 3 weeks after initiation of paclitaxel (T1), between paclitaxel and anthracycline regimens (T2), or prior to surgery (T3). A personalized ctDNA test was designed to detect 16 patient-specific mutations (from whole exome sequencing of pretreatment tumor) in cfDNA by ultra-deep sequencing. At T0, 61 of 84 (73%) patients were ctDNA-positive, which decreased over time (T1-35%; T2-14%; T3-9%). Patients who remained ctDNA-positive at T1 were significantly more likely to have residual disease after NAC (83% non-pCR) compared to those who cleared ctDNA (52% non-pCR; OR 4.33, P=0.012). After NAC, all patients who achieved pCR were ctDNA-negative (n=17, 100%). For those who did not achieve pCR (n=43), ctDNA-positive patients (14%) had significantly increased risk of metastatic recurrence (HR 10.4; 95% CI, 2.3–46.6); interestingly, patients who did not achieve pCR but were ctDNA-negative (86%) had excellent outcome, similar to those who achieved pCR (HR 1.4; 95% CI, 0.15–13.5). Lack of ctDNA clearance was a significant predictor of poor response and metastatic recurrence, while clearance was associated with improved survival regardless of pCR status. Personalized monitoring of ctDNA during NAC may aid in real-time assessment of treatment response and help fine-tune pCR as a surrogate endpoint of survival.Competing Interest StatementConflict of interest disclosures: The following authors are employees of Natera, Inc. (Himanshu Sethi, Hsin-Ta Wu, Raheleh Salari, Antony Tin, Svetlana Shchegrova, Hemant Pawar, Paul Billings, Alexey Aleshin, Maggie Louie, Bernhard Zimmermann). Laura van ’t Veer is co-founder, stockholder and part-time employee of Agendia NV. The rest of the authors declare no potential conflicts of interest.Funding StatementThis study was funded in part by the Breast Cancer Research Foundation (BCRF) (L.J.V. Veer), and the Breast Cancer Research Fund at UCSF (L.J.V. Veer) and NIH/NCI P01CA210961 (L.J. Esserman). ctDNA analysis was provided by Natera without cost.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request from the I-SPY 2 TRIAL Consortium.